Nkarta Expects Initial Data From CAR NK Cell Therapy In Blood Cancer In 2022

Nkarta Inc NKTX has updated guidance on initial data readout of Phase 1 trial of NKX101 in relapsed or refractory acute myeloid leukemia or higher-risk myelodysplastic syndromes.
Data from the engineered CAR NK cell therapy candidate targeting the NKG2D ligand is expected in 1H of 2022, against the end of 2021 expected earlier.
Multiple factors have affected the cadence of the NKX101 Phase 1 study, including the use of haplomatched (half-matched or partially-matched) donor-derived cells, the requirement for a staggered enrollment of patients that was longer than expected initially, and COVID-19 related disruptions.
Additionally, Nkarta dosed the first patient in Phase 1 trial of NKX019 in advanced B-cell malignancies.
NKX019 is an NK cell immunotherapy engineered to eradicate tumors expressing CD19, a validated B-cell cancer target.
Related: Nkarta, CRISPR Join Forces On CAR-NK Development For Cancer.
Price Action: NKTX shares closed 4.56% higher on Thursday.